ANVISA Approves First Marijuana-based Medicinal Product in Brazil

Approval covers a phytopharmaceutical product that contains cannabidiol and a concentration of less than 0.2 percent THC, the substance with psychotropic effects.

RIO DE JANEIRO, BRAZIL - The National Health Surveillance Agency (ANVISA) approved on Wednesday, April 22nd, the registration of the first marijuana-based product in the country.

It is a phytopharmaceutical product that contains cannabidiol and a concentration of less than 0.2 percent THC, the substance with psychotropic effects.

The product may be sold in pharmacies, provided there is a medical prescription. ANVISA states that the drug will be used in cases where there is no therapeutic alternative, but failed to specify which diseases would be benefited.

ANVISA has not reported the name of the drug. The product is manufactured . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?